Toggle Main Menu Toggle Search

Open Access padlockePrints

Carbogen breathing increases prostate cancer oxygenation: A translational MRI study in murine xenografts and humans

Lookup NU author(s): Dr Ross Maxwell, Ian Wilson


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Hypoxia has been associated with poor local tumour control and relapse in many cancer sites, including carcinoma of the prostate. This translational study tests whether breathing carbogen gas improves the oxygenation of human prostate carcinoma xenografts in mice and in human patients with prostate cancer. A total of 23 DU145 tumour-bearing mice, 17 PC3 tumour-bearing mice and 17 human patients with prostate cancer were investigated. Intrinsic susceptibility- weighted MRI was performed before and during a period of carbogen gas breathing. Quantitative R2* pixel maps were produced for each tumour and at each time point and changes in R2* induced by carbogen were determined. There was a mean reduction in R2* of 6.4% (P=0.003) for DU145 xenografts and 5.8% (P=0.007) for PC3 xenografts. In all, 14 human subjects were evaluable; 64% had reductions in tumour R2* during carbogen inhalation with a mean reduction of 21.6% (P=0.0005). Decreases in prostate tumour R2* in both animal models and human patients as a result of carbogen inhalation suggests the presence of significant hypoxia. The finding that carbogen gas breathing improves prostate tumour oxygenation provides a rationale for testing the radiosensitising effects of combining carbogen gas breathing with radiotherapy in prostate cancer patients. © 2009 Cancer Research UK.

Publication metadata

Author(s): Alonzi R, Padhani AR, Maxwell RJ, Taylor NJ, Stirling JJ, Wilson JI, D'Arcy JA, Collins DJ, Saunders MI, Hoskin PJ

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2009

Volume: 100

Issue: 4

Pages: 644-648

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Nature Publishing Group


DOI: 10.1038/sj.bjc.6604903

PubMed id: 19190629


Altmetrics provided by Altmetric


Funder referenceFunder name
C39/A3987Cancer Research UK